Colliers Securities analyst Kyle Bauser reiterated a Buy rating on Semler Scientific (NASDAQ:SMLR) on Tuesday, setting a price target of $182, which is approximately 21.53% above the present share price of $149.76.
Bauser expects Semler Scientific to post earnings per share (EPS) of $1.00 for the fourth quarter of 2021.
The current consensus among 3 TipRanks analysts is for a Strong Buy rating of shares in Semler Scientific, with an average price target of $185.67.
The analysts price targets range from a high of $200 to a low of $175.
In its latest earnings report, released on 06/30/2021, the company reported a quarterly revenue of $14.31 million and a net profit of $6.46 million. The company's market cap is $1.01 billion.
According to TipRanks.com, Colliers Securities analyst Kyle Bauser is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 19.3% and a 57.69% success rate.
Semler Scientific, Inc. engages in the provision of technology and software solutions to improve the clinical effectiveness of healthcare providers. Its multi-test service platform, WellChec, comprehensively evaluate its customers' patients for chronic disease, including heart attacks and strokes, using its QuantaFlo product as well as other tests. The company was founded by Herbert J. Semler and Shirley L. Semler on August 9, 2007 and is headquartered in San Jose, CA.